NorthRock Partners LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 22.9% during the 1st quarter, HoldingsChannel.com reports. The fund owned 263 shares of the biopharmaceutical company’s stock after selling 78 shares during the period. NorthRock Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $253,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. West Paces Advisors Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares in the last quarter. Fortitude Family Office LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $31,000. MCF Advisors LLC increased its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares during the last quarter. Criterion Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $37,000. Finally, BOK Financial Private Wealth Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $37,000. 83.31% of the stock is currently owned by institutional investors.
Insider Activity at Regeneron Pharmaceuticals
In related news, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the transaction, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the sale, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The disclosure for this sale can be found here. In the last quarter, insiders have sold 65,074 shares of company stock valued at $64,546,123. 7.48% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Read Our Latest Analysis on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Trading Down 1.6 %
Regeneron Pharmaceuticals stock traded down $17.94 during trading hours on Monday, reaching $1,082.11. 431,230 shares of the company’s stock were exchanged, compared to its average volume of 472,697. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The firm’s 50 day simple moving average is $1,016.19 and its 200 day simple moving average is $967.07. Regeneron Pharmaceuticals, Inc. has a twelve month low of $715.54 and a twelve month high of $1,106.16. The firm has a market capitalization of $119.24 billion, a PE ratio of 31.97, a PEG ratio of 2.27 and a beta of 0.13.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). The company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- Investing in Travel Stocks Benefits
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.